Daniel Bradbury Sells 4,632 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury sold 4,632 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $20.03, for a total transaction of $92,778.96. Following the completion of the transaction, the director now directly owns 66,854 shares in the company, valued at $1,339,085.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Daniel Bradbury also recently made the following trade(s):

• On Friday, July 7th, Daniel Bradbury sold 50,000 shares of Castle Biosciences stock. The shares were sold at an average price of $20.39, for a total transaction of $1,019,500.00.

Castle Biosciences Trading Down 1.4 %

Shares of CSTL opened at $19.66 on Friday. Castle Biosciences, Inc. has a 12 month low of $9.26 and a 12 month high of $30.08. The firm has a fifty day simple moving average of $16.99 and a 200 day simple moving average of $20.01. The stock has a market capitalization of $527.08 million, a price-to-earnings ratio of -5.87 and a beta of 0.84.

Castle Biosciences (NASDAQ:CSTL) last announced its earnings results on Wednesday, August 2nd. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.31. The business had revenue of $50.14 million during the quarter, compared to analysts’ expectations of $43.51 million. Castle Biosciences had a negative net margin of 53.04% and a negative return on equity of 22.57%. As a group, research analysts predict that Castle Biosciences, Inc. will post -3.75 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on CSTL shares. BTIG Research dropped their target price on shares of Castle Biosciences from $38.00 to $30.00 in a report on Thursday, June 15th. Robert W. Baird raised their target price on shares of Castle Biosciences from $25.00 to $30.00 in a report on Thursday, August 3rd. KeyCorp dropped their target price on shares of Castle Biosciences from $37.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, August 4th. SVB Securities cut their price target on Castle Biosciences from $50.00 to $35.00 in a report on Monday, June 5th. Finally, Scotiabank cut their price target on Castle Biosciences from $54.00 to $33.00 in a report on Wednesday, June 7th.

Hedge Funds Weigh In On Castle Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the company. American International Group Inc. lifted its stake in Castle Biosciences by 5.2% in the second quarter. American International Group Inc. now owns 11,130 shares of the company’s stock valued at $244,000 after acquiring an additional 552 shares during the last quarter. First Republic Investment Management Inc. lifted its stake in Castle Biosciences by 6.2% in the 1st quarter. First Republic Investment Management Inc. now owns 10,770 shares of the company’s stock valued at $245,000 after purchasing an additional 631 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Castle Biosciences by 5.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,573 shares of the company’s stock worth $263,000 after purchasing an additional 642 shares during the period. Baird Financial Group Inc. grew its holdings in Castle Biosciences by 4.9% during the first quarter. Baird Financial Group Inc. now owns 14,349 shares of the company’s stock worth $644,000 after purchasing an additional 674 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Castle Biosciences by 61.2% in the third quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company’s stock valued at $47,000 after buying an additional 691 shares during the period. 85.75% of the stock is owned by institutional investors.

About Castle Biosciences

Castle Biosciences, Inc, a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma.